CNSDose® is a proprietary, commercially-available battery of pharmacogenomic tests (CNSDose, LLC).
The test battery includes evaluation of genetic variations in the genes coding for:
1. Cytochrome P450 isoenzymes CYP2D6 and CYP2C19. Other CYP450 isoenzymes are not evaluated as of February 2017.
2. UGT1A1 (UDP-glucuronosyltransferase 1A1) which is a phase II metabolism enzyme
3. Two ATP-binding cassette (ABC) efflux transporters (ABCB1 and ABCC1) that affect the entry of certain molecules across the blood–brain barrier
Bousman CA, Müller DJ, Ng CH, Byron K, Berk M, Singh AB. Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. Pharmacogenet Genomics. 2017 Jan;27(1):1-6. PubMed PMID: 27779571; PubMed Central PMCID: PMC5152629.
Singh AB. Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. Clin Psychopharmacol Neurosci. 2015 Aug 31;13(2):150-6. PubMed PMID: 26243841; PubMed Central PMCID: PMC4540033.
Singh AB, Bousman CA, Ng CH, Byron K, Berk M. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry. 2012 Nov 27;2:e198. PubMed PMID: 23188198; PubMed Central PMCID: PMC3565756.
Copyright © 2017, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.